GEXVal CEO Speaks at University of Tokyo Hospital Drug Discovery Training Program
2025/11/21
GEXVal Inc.November 21, 2025 GEXVal CEO Delivers a Lecture at University of Tokyo Hospital TR/Academia Drug Di […]
GEXVal Receives FDA Orphan Drug Designation for GXV-001 in Fragile X Syndrome
2025/11/19
GEXVal Inc.November 19, 2025 GEXVal Receives FDA Orphan Drug Designation for GXV-001 in Fragile X Syndrome GEX […]
GEXVal CEO to Speak at China Healthcare Summit 2025
2025/10/20
GEXVal Inc.October 20, 2025 GEXVal CEO Invited and to Speak at BioCentury-BayHelix China Healthcare Summit 2 […]
GEXVal CTO to Present at CBI Annual Meeting 2025
2025/10/17
GEXVal Inc.October 17, 2025 GEXVal CTO to Present at Chemo-Bio Informatics Society (CBI) Annual Meeting 2025 […]